✔ 100% Money-Back Guarantee on Eligible Items
✔ Prices Displayed in Your Local Currency
✔ Final Price = No Surprise Import Fees
✔ Complimentary Insured Worldwide Shipping on Qualifying Orders
✔ Select Collector & Specialty Pieces May Require Secured Delivery Handling
by Jason Hsu (Author), Dimitrios Iliopoulos (Author)
Janet Yellen, the Fed Chair, recently said that the valuations of small-cap biotechnology companies are substantially stretched. Biotechnology is a relatively new science and during the last few years there is an increasing number of new biotech start-up companies and also M&A activity between biotech start-ups and large biotechnology and pharmaceutical companies. Few years ago, we observed one of the largest acquisitions in the biotech sector, by having Amgen buying Onyx Pharmaceuticals for more than $9 billion dollars. More recently, Moderna Therapeutics, a biotech company developing mRNA therapeutics, broke the record of VC funding, raising $450 million dollars in a single round of funding, without having a product in the market. All these recent events raise an important question: what are the valuation financial models used in the biotechnology industry? How could we value a company having negative cash flows for several years, without any product in the market? How do we value a company developing a CRISPR therapeutics currently in the preclinical level? Is there any difference on valuating a phase II drug against arthritis vs a phase II anti-cancer drug? This book is aiming to answer these essential questions by describing the key aspects of the drug discovery process, including novel financial models used for valuation of biotech companies. Furthermore, we have created new biotech valuation cases providing to the reader a practical guide for valuation of any biotech product or company.
Author Biography
Dimitrios Iliopoulos is an Associate Professor of Medicine, in the Vatche and Tamar Manoukian Division of Digestive Diseases at UCLA David Geffen School of Medicine and the Founding Director of the UCLA Center for Systems Biomedicine, a high technology center combining novel technologies aiming to expedite the drug discovery process for different human diseases. Furthermore, he is founder of Algorithm Therapeutics Inc, a biotech company developing epigenetic drugs for patients with inflammatory diseases. He started his academic career as an Assistant Professor at Dana-Farber Cancer Institute and Harvard Medical School. He has received an Executive MBA degree from UCLA Anderson School of Management, having a specialization in financial valuation and modeling of the biotechnology and healthcare sectors. More recently, Dr. Iliopoulos received a certificate from Stanford Graduate School of Business on Mergers & Acquisitions. Dimitrios is a consultant to several pharma and biotech companies and has collaborated with venture capital firms and major investment banks in projects related to biotech company financial valuation. Jason Hsu is the CEO and Chairman of Rayliant Global Advisors, an investment management firm focused on smart beta strategies tailored to the Asian markets as well as Chinese equity strategies targeted at foreign institutional investors. Jason graduated with a BS in physics from the California Institute of Technology, an MS in Finance from Stanford University and a PhD in Finance from UCLA, where he conducted research on the equity premium and portfolio allocations. Currently, he is a Member of the Board of Directors at the Anderson School of Management at UCLA, as well as an Adjunct Professor of Finance. He is also a co-founder of Research Affiliates, currently serving as a Vice Chairman and Advisor. Building on his pioneering work on the RAFI Fundamental Index approach to investing, he has published numerous articles on the topic, notably including "A survey of alternative equity index strategies", which won a 2011 Graham and Dodd Schroll and the Readers' Choice Award from the CFA Institute. In 2013, he received the William F. Sharpe Award for Best New Index Research. Dr. Hsu has authored more than 40 peer-reviewed articles and he is an Associate Editor in the Journal of Investment Management.
- In stock, ready to ship
- ✔ Authenticity Guaranteed — Verified Designer Goods
- ✔ Sourced from Authorized European/U.S. Luxury Distributors
- ✔ Secure Checkout — SSL Encrypted Payments
- ✔ Fast Global Delivery — 3–11 Business Days
- ✔ Easy Returns on Eligible Items
- ✔ 100% Money-Back Guarantee — Full Refund if Not Satisfied
AUTHENTICITY GUARANTEED
Reserved for you — complete your purchase to secure this piece.
OFFICIALLY AUTHORIZED RESELLER
Discover Officially Authorized Authentic Items at STORE7994.com - Certificates Available on Request!
Independently verified for store quality and customer safety.
Trust score: 91/100
All designer items offered by STORE 7994 are sourced from trusted luxury distributors and verified through independent authentication services.
Learn how STORE 7994 authenticates luxury items
Guaranteed Authentic — Includes Brand Documentation & Third-Party Verification Options.
Shipping information
- Free Shipping* on all orders over $300 USD to most countries* Estimated delivery: 2-5 business days Mon-Sat to U.S., CA, EU etc.
- Tracking available: DHL Express
- Store 7994 Shipping policy
- Global delivery in 3–9 business days (location dependent).
- Free Worldwide Shipping $300+. International duties & VAT are calculated by destination country and may be collected upon delivery. UK orders are subject to 20% import VAT upon delivery.
Our innovation isn’t just in the brands we carry — it’s in the way we connect them. From our automation engine that keeps collections globally updated to our commitment to authenticity-first presentation, STORE 7994 exists where timeless design meets modern precision.
Every product we offer is:
Elevated · Intentional · Exclusive · Authentic
STORE 7994 is an authorized reseller of luxury fashion houses. Certificates and proof of authenticity are available to brand owners and partners upon request.
Returns & Refunds
We want you to shop with confidence at STORE 7994. If your purchase does not meet expectations, eligible items may be returned under the conditions below.
Return Eligibility
Items must be unused, unworn, and in original condition with all tags, packaging, and accessories included. Items showing any signs of wear or damage will not be accepted.
Return Window
Return requests must be made within 14 days of delivery.
Return Shipping
Customers are responsible for return shipping costs unless the item is defective, damaged, or incorrect.
Luxury Items
Items valued over $1,000 may be subject to a 7% restocking fee upon approved return.
Non-Returnable Items
For hygiene and product integrity reasons, the following items are final sale once opened or used:
• Underwear
• Fragrances
• Any worn or used items
Made-to-Order Items
Custom-designed products, including STORE 7994 hoodies, are made exclusively for each customer and are final sale. These items are not eligible for return or exchange unless defective or incorrect.
If you receive a defective or incorrect item, please contact us and we will make it right.
International Shipping & Duties
Many of our products ship directly from trusted international partners. Any applicable customs duties or import taxes are calculated at checkout and are non-refundable, even if the item is returned.
Returns & Associated Fees
All approved returns are subject to a $24 return processing fee. For international orders, duties, taxes, and return fees will be deducted from the original payment.
Shipping Policy
Complimentary shipping is offered on orders over $300. Orders below this threshold are subject to standard shipping rates at checkout.
